Результаты поиска

Paeoniflorin Ameliorates BiPN by Reducing IL6 Levels and Regulating PARKIN-Mediated Mitochondrial Autophagy.

BACKGROUND: Bortezomib-induced peripheral neuropathy (BiPN) is a common complication of multiple myeloma (MM) treatment that seriously affects the quality of life of patients. The purpose of the present study was to explore the therapeutic effect of paeoniflorin on BiPN and its possible mechanism. METHODS: ELISA was used to measure the level of interleukin-6 (IL6) in the plasma of MM patients, and bioinformatics analysis was used to predict the mechanism underlying the effect of paeoniflorin on peripheral neuropathy. Cell and animal models of BiPN were constructed to evaluate mitochondrial fu

Совпадение в полном тексте источника
… Yin Y, Qi X, Qiao Y, et al. The association of neuronal stress with activating transcription factor 3 in dorsal root ganglion of in vivo and in vitro models of bortezomib-induced neuropathy. Curr Cancer Drug Targets . 2019;19(1):50–64. doi: 10.2174/1568009618666181003170027 11. …

Propranolol: A "Pick and Roll" Team Player in Benign Tumors and Cancer Therapies.

Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combin

Совпадение в полном тексте источника
… Qi M. Peng C. Zhou C. Su J. Zeng W. Liu H. Zhang J. Chen M. Shen M. Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma Oncotarget 2017 9 802 811 10.18632/oncotarget.22696 29416656 PMC5787512 76. Kokolus K.M. …

Clinicopathologic characteristics, metastasis-free survival, and skeletal-related events in 628 patients with skeletal metastases in a tertiary orthopedic and trauma center.

BACKGROUND: Skeletal-related events (SREs) due to bone metastases (BM) significantly impact the morbidity and mortality of cancer patients. The present study sought to investigate clinicopathological characteristics, metastasis-free survival (MFS), and SREs in patients referred to a tertiary orthopedic and trauma center. METHODS: Data were retrieved from electronic health records (n=628). Survival curves were estimated utilizing the Kaplan-Meier method. The Cox regression model was used to determine factors influencing MFS based on estimated hazard ratios (HRs). RESULTS: Breast (55.8%) and l

Совпадение в полном тексте источника
… Ma W Peltzer K Qi L Xu G Liu Z Wang J Female sex is associated with a lower risk of bone metastases and favourable prognosis in non-sex-specific cancers BMC Cancer 2019 19 1001 10.1186/s12885-019-6168-1 31653236 PMC6815063 42. …

Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis.

IntroductionInterleukin-16 (IL-16) is a chemotactic cytokine that is found to increase in Cancer and cardiovascular diseases (CVD). Single nucleotide polymorphisms (SNPs) in IL16 were associated with diseases. Thus, we conducted a systematic review and meta-analysis to evaluate possible associations between IL16 rs4778889, rs11556218, rs4072111, and rs1131445 SNPs and the risk for cancer or CVD.Materials and methodsThis study was performed according to the PRISMA statement. Medline, Web of Science, and Scopus databases were systematically reviewed, and a meta-analysis was conducted.ResultsThe

Совпадение в полном тексте источника
… Yang L , Liu J , Qi G , Yue W . Interleukin-16 gene polymorphism is associated with acute coronary syndrome in the Chinese Han population . Int J Clin Exp Med . 2018 ; 11 : 2624 – 2629 . 74. Moher D , Liberati A , Tetzlaff J , Altman DG , and PRISMA Group . …

CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer.

Gastric cancer (GC) is one of the most commonly diagnosed malignancies and, unfortunately, still has a high mortality rate. Recent research points to CAR-T immunotherapy as a promising treatment for this disease. Using genetically engineered T cells designed to target a previously selected antigen, researchers are able to harness the natural anti-tumor activity of T cells. For therapy to be successful, however, it is essential to choose antigens that are present on tumor cells but not on healthy cells. In this review, we present an overview of the most important targets for CAR-T therapy in th

Совпадение в полном тексте источника
… Qi X. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition Oncogene 2018 37 3022 3038 10.1038/s41388-018-0204-5 29535422 PMC5978807 23. Wada N. Kurokawa Y. Miyazaki Y. Makino T. Takahashi T. Yamasaki M. Doki Y. …

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.

Elderly transplant-ineligible (NTE) patients represent the majority of patients affected by multiple myeloma (MM). Elderly patients are a highly heterogeneous population, with large variability in health and functional status. Thus, choosing their optimal treatment is challenging. A wide range of first-line treatments is available, and novel-agent combinations, including monoclonal antibodies (mAbs), have recently entered clinical practice. The combination of the anti-CD38 mAb daratumumab with bortezomib, melphalan and prednisone (Dara-VMP) or lenalidomide and dexamethasone (Dara-Rd) demonstra

Совпадение в полном тексте источника
… Fujisaki T., Ishikawa T., Takamatsu H., Suzuki K., Min C.K., Lee J.H., Wang J., Carson R., Crist W., Qi M., et al. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: Subanalysis of the randomized phase 3 ALCYONE trial. Ann. …

Adverse Events of Oncologic Immunotherapy and Their Management.

Over the past two decades, immunotherapy has emerged as a promising treatment option for patients with cancer. However, newer versions of immunotherapy, such as checkpoint inhibitors, may be associated with unusual adverse effects (AEs) that can range in severity from mild to life-threatening. Unlike common AEs of conventional chemotherapy, which have a predictable nadir or cyclic pattern after administration, AEs of these newer immunotherapies are variable, depending on the type of immunotherapy, route of administration, and mechanism of action. The onset and resolution of these AEs may be pr

Совпадение в полном тексте источника
… Chen J, Xiao-Zhong G, Qi XS. Clinical outcomes of specific immunotherapy in advanced pancreatic cancer: A systematic review and meta-analysis. J Immunol Res. 2017;2017:8282391. doi: 10.1155/2017/8282391. 3. Printz C. …

The Role of Macrophage in the Pathogenesis of Osteoporosis.

Osteoporosis is a systemic disease with progressive bone loss. The bone loss is associated with an imbalance between bone resorption via osteoclasts and bone formation via osteoblasts. Other cells including T cells, B cells, macrophages, and osteocytes are also involved in the pathogenesis of osteoporosis. Different cytokines from activated macrophages can regulate or stimulate the development of osteoclastogenesis-associated bone loss. The fusion of macrophages can form multinucleated osteoclasts and, thus, cause bone resorption via the expression of IL-4 and IL-13. Different cytokines, endoc

Совпадение в полном тексте источника
… Qi J. Zhou Q. Rao D.S. Qiu S. Protective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats PLoS ONE 2017 12 e0186012 10.1371/journal.pone.0186012 29045447 PMC5646759 98. Reis L.C. Ramos-Sanchez E.M. Petitto-Assis F. Nerland A.H. Hernandez-Valladares M. …

Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) which may represent a valid model for high-risk MM. This disease is associated with a very poor prognosis, and unfortunately, it has not significantly improved during the last three decades. New high-throughput technologies have allowed a better understanding of the molecular basis of this disease and moved toward risk stratification, providing insights for targeted therapy studies. This knowledge, added to the pharmacogenetic profile of new and old agents in the analysis of efficacy and safety, could

Совпадение в полном тексте источника
… Chang H., Qi X., Yeung J., Reece D., Xu W., Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk. Res. 2009;33:259–262. doi: 10.1016/j.leukres.2008.06.027. 17. Eymin B., Gazzeri S., Brambilla C., Brambilla E. …

ESICM LIVES 2016: part two : Milan, Italy. 1–5 October 2016

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Vasculopathy as a mechanical barrier to cancer spread: Clinical evidence and a rheology-based model in lung cancer and other solid tumors.

Metastatic dissemination in lung cancer (LC) and other solid tumors is influenced not only by tumor-intrinsic biology and immune-inflammatory responses, but also by the physical properties of the vascular system through which circulating tumor cells (CTCs) migrate. Peripheral arterial disease (PAD), particularly when associated with aneurysmal dilation, is frequent among long-term smokers and is characterized by chronic vascular inflammation and altered hemodynamics. We hypothesized that PAD-related vascular remodeling and rheological alterations may influence tumor metastatic capacity. Throug

Совпадение в полном тексте источника
… Xie S., Wu Z., Qi Y., Wu B., Zhu X. The metastasizing mechanisms of lung cancer: recent advances and therapeutic challenges. Biomed. Pharmacother. 2021;138 doi: 10.1016/j.biopha.2021.111450. 2. Siegel R.L., Giaquinto A.N., Jemal A. Cancer statistics, 2024. CA Cancer J. …

Predictive value of the prothrombin time-to-albumin ratio for 28- and 90-day mortality in lung cancer patients admitted to the intensive care unit: A retrospective cohort study.

This retrospective observational study assesses the prognostic utility of the prothrombin time/albumin ratio (PAR) for 28- and 90-day mortality in patients with lung cancer. A total of 959 patients with lung cancer were included from the Medical Information Mart for Intensive Care IV v2.2 database (USA). The time origin was defined as intensive care unit (ICU) admission, and patients were censored at 28 and 90 days post-admission for the respective outcome analyses. The main variables were the PAR index, 28-day mortality, and 90-day mortality. Relevant clinical data were extracted, and Cox reg

Совпадение в полном тексте источника
… [23] Qi Y, Fu J. Research on the coagulation function changes in non small cell lung cancer patients and analysis of their correlation with metastasis and survival. J BUON. 2017;22:462–7. [24] Bayleyegn B, Adane T, Getawa S, Aynalem M, Kifle ZD. …

Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer.

Renal cell carcinoma (RCC) and prostate cancer (PCa) are among the most prevalent and therapeutically challenging malignancies of the genitourinary system, particularly in advanced or metastatic stages. For advanced/metastatic RCC, targeted agents such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have improved progression-free and overall survival. For metastatic castration-sensitive PCa, androgen deprivation therapy (ADT) combined androgen receptor pathway inhibitors (ARPIs) with or without chemotherapy remains the standard of care. Despite these advances, ther

Совпадение в полном тексте источника
… Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18:1751–9. 45. Zhao X, Zhang Z, Li H, Huang J, Yang S, Xie T, Huang L, Yue D, Xu L, Wang L, Zhang W, Zhang Y. …

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic.

Multiple myeloma (MM) is an incurable hematological malignancy with significant clinical and biological heterogeneity. Despite development and refinement of numerous prognostic models for MM, challenges with accurate and reliable risk stratification remain, highlighted by unexpected, early relapse or progression of disease in patients termed functional high-risk (FHR). To improve decision-making and optimise outcome, there is an unmet need for precise identification of high-risk (HR) patients, to enable tailored therapeutic strategies. With a complex and rapidly evolving treatment landscape, a

Совпадение в полном тексте источника
… Shen S, Qi W, Liu X, Zeng J, Li S, Zhu X, et al. From virtual to reality: innovative practices of digital twins in tumor therapy. J Transl Med. (2025) 23(1):348. 10.1186/s12967-025-06371-z 75. Asghar US, Chung C. Application of digital twins for personalized oncology. …

Histone Modifier KANSL2 является практически осуществимым биомаркером в Мультимиломе.

Эпигенетические отклонения являются ключевыми движущими силами множественной миеломы, однако адресная терапия, использующая эпигенетические изменения, еще не установлена. Объединяя клинические и молекулярные наборы пациентов с множественной миеломой с непредвзятым генетическим экраном в vivo, мы определили подгруппу 2 (KANSL2) КАТ8, регулирующую комплекс NSL, как гистонную послетрансляционную модификацию, связанную с онкогене. Высокое выражение KANSL2 было связано с неблагоприятным прогнозом у пациентов с множественной миеломой. Генетические модели " наживы " и " потери функцион

Совпадение в полном тексте источника
… Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 2014;13:1142–54. 55. Clive S, Woo MM, Nydam T, Kelly L, Squier M, Kagan M. …

Premature hair graying: a multifaceted phenomenon.

Premature hair graying (PHG) is the early loss of natural hair color, influenced by genetic, biological, and environmental factors. This review discusses the significant psychological impacts of PHG and explores its underlying mechanisms, related health conditions, and available treatments. The review examines the roles of genetics, oxidative stress, and lifestyle factors such as smoking and diet in premature graying. It also considers associated medical conditions and current and emerging treatment options. This overview aims to improve understanding of PHG and its broader implications.

Совпадение в полном тексте источника
… Biol Rev Camb Philos Soc . 2021 ; 96 ( 1 ): 107 – 128 . 32965076 10.1111/brv.12648 14 Wang S , Kang Y , Qi F , Jin H . Genetics of hair graying with age . Ageing Res Rev . 2023 ; 89 : 101977 . 37276979 10.1016/j.arr.2023.101977 15 Choi YJ , Yoon TJ , Lee YH . …

Old Drugs, New Battles: Unleashing Repurposed Drug Classes in Triple-Negative Breast Cancer Treatment.

Cancer remains a major global health challenge, with triple-negative breast cancer (TNBC) representing one of the most aggressive and difficult-to-treat subtypes, characterized by poor prognosis and limited therapeutic options. Current treatments, including chemotherapy, are hindered by high recurrence rates, drug resistance, and severe side effects, highlighting the urgent need for novel therapeutic strategies to address these challenges. Drug repurposing, which involves the application of existing FDA-approved (Food and administration) drugs for new oncological uses, offers a cost-effective

Совпадение в полном тексте источника
… He L., Fu Y., Tian Y., Wang X., Zhou X., Ding R.B., Qi X., Bao J. Antidepressants as Autophagy Modulators for Cancer Therapy. Molecules. 2023;28:7594. doi: 10.3390/molecules28227594. 52. Haddad N., Gamaethige S.M., Wehida N., Elbediwy A. …

Life's essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants.

BackgroundThis study aimed to explore the association between Life's Essential 8 (LE8) and the risk of cancer occurrence and cancer-associated mortality across 24 cancer types. The cardiovascular health (CVH) score is constructed based on the overall LE8 score, providing a more direct measure of CVH and its potential relationship with cancer risk.MethodsThis cohort enrolled participants from a prospective cohort of the United Kingdom Biobank, including individuals aged 37-73 years, with 332,417 cancer-free participants. CVH scores were assessed using the LE8 metrics. The primary outcome of thi

Совпадение в полном тексте источника
… Wang X, Ma H, Li X, Heianza Y, Manson JE, Franco OH, Qi L. Association of cardiovascular health with life expectancy free of cardiovascular disease, diabetes, cancer, and dementia in UK adults. JAMA Intern Med. 2023;183:340–9. 10.1001/jamainternmed.2023.0015. 33. …

Role of Chimeric Antigen Receptor T-Cells in the Evolving Therapeutic Landscape of Multiple Myeloma: A Literature Review.

Multiple myeloma (MM) is a quotidian malignant disorder of plasma cells. It is hallmarked by the uncontrolled growth of bone marrow plasma cells, leading to multiorgan dysfunction. Despite ongoing advancements in remedies, including chemotherapy, radiotherapy, immunomodulatory drugs, stem cell transplantations, and countless other lines of treatment, the management of MM remains a challenge. Recent studies indicate promising outcomes with chimeric antigen receptor T-cell (CAR-T) therapy, especially in patients who have previously undergone other treatments. This literature review aims to explo

Совпадение в полном тексте источника
… Zhang X, Ouyang C, Sun G, Liu H, Qi J, Suo X. Exp Ther Med. 2023;26:471. doi: 10.3892/etm.2023.12170. 29. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma. Duan D, Wang K, Wei C, et al. …

Научные достижения в отношении роли остеобластов и их производных в разработке, повторении и удалении метастаза злокачественных опухолей костей: обзор повествования.

Злоумышленные опухоли костей, включая первичные опухоли костей, такие, как остеосаркома (OS), саркома Евинга (ES) и множественная миелома, а также вторичные опухоли костей от рака простаты и груди, создают значительный риск смертности. Остеобласт (OBs) и их производные играют важнейшую роль в развитии, повторении и метастазе этих опухолей. ОБ пропагандируют события, связанные с метастазом, включая остеокластную дифференциацию и распространение. Их производные, включая внеклеточные везикли и цитокины, модулярируют реконструкцию костей и развитие опухоли по различным сигнальным путям. Недавние и

Совпадение в полном тексте источника
… Jun-qi Luo et al. demonstrated that exosomal phosphoglycerate mutase 1 (PGAM1) promotes angiogenesis in metastatic PCa patients through both in vivo and in vitro experiments. …